High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer

FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors

(2019) Leigh Marcus et al.   CLINICAL CANCER RESEARCH

PD‐L1 expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti‐PD‐L1 antibodies

(2019) Soomin Ahn et al.   HISTOPATHOLOGY

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

(2018) Karina Kulangara et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

(2018) Charles S. Fuchs et al.   JAMA Oncology

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

(2018) T A Chan et al.   ANNALS OF ONCOLOGY

Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report

(2018) Haibo Mou et al.   BMC CANCER

PD-L1 expression in extrahepatic cholangiocarcinoma

(2017) Dirk Walter et al.   HISTOPATHOLOGY

Cholangiocarcinoma — evolving concepts and therapeutic strategies

(2017) Sumera Rizvi et al.   Nature Reviews Clinical Oncology

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

(2017) Maria Vittoria Dieci et al.   SEMINARS IN CANCER BIOLOGY

PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma

(2017) Ke Ma et al.   Oncology Letters

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma

(2017) Jacqueline Fontugne et al.   Oncotarget

PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study

(2017) Hyojin Kim et al.   Oncotarget

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

(2016) Pedro N Aguiar et al.   Immunotherapy

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

(2016) Joohee Sul et al.   ONCOLOGIST

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028

(2015) Y.J. Bang et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

(2015) Therese Phillips et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Cholangiocarcinoma

(2014) Nataliya Razumilava et al.   LANCET

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER